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Abstract. Assessment of post-treatment disease activity among patients with cystic echinococcosis (CE) is insensitive
using detection of CE-specific total IgG antibody. This study investigated whether serum concentrations of CE-specific
IgG subclasses 1-4 correlate better with disease activity than total IgG. We studied a cohort of patients (n  28) with
symptomatic CE treated with anthelminthic drugs and surgery and who were followed up clinically and radiologically for
a mean of 5.6 years (range 3–12 years). Serial archived sera collected during follow-up were retrospectively analyzed
by enzyme-linked immunosorbent assays using crude horse hydatid cyst fluid as antigen. Changes in concentrations of
antibodies were correlated with clinical and radiologic outcome. At diagnosis, concentrations of CE-specific total IgG,
IgG1, and IgG2 antibodies were significantly elevated in a greater proportion of patients compared with IgG3 and IgG4
antibodies. During post-treatment follow up, the IgG2 antibody response provided the best correlate of disease activity.
INTRODUCTION
Cystic echinococcosis (CE) is caused by infection with the
larval stage (hydatid) of the cestode Echinococcus granulosus
and is one of the world’s major zoonotic infections.1 Humans
acquire infection by accidental ingestion of E. granulosus eggs
voided in the feces of infected dogs and the disease is com-
mon in parts of the world where there is close contact be-
tween the intermediate and definitive hosts, usually sheep
and dogs, respectively.2 Cystic echinococcosis in humans usu-
ally presents with symptoms associated with the presence of
fluid-filled cysts in the liver, lungs, or other viscera, and di-
agnosis is usually established by a combination of radiology
and serology.3 Treatment modalities for CE include chemo-
therapy and surgery.2 Although surgery still remains the most
common approach to treatment of CE throughout the world,
long-term albendazole therapy has significant efficacy in ap-
proximately 70% of the cases.4 Albendazole is active against
both cyst germinal membrane and protoscolices in animal
models;5,6 praziquantel is protoscolicidal and may act syner-
gistically with albendazole.7,8 However, the optimum dura-
tion and dosages of these drugs and their use in relation to
surgical intervention have not been definitively determined.
This is partly because CE is a chronic disease in which
changes in disease activity and treatment effect are difficult to
measure. As a result, no standardized approach to treatment
has emerged.
Longitudinal assessments of hydatid cyst viability are com-
monly made using serial radiology with or without serial
serology. However, there is no test for cure and follow-up
surveillance is therefore required for many years. At the Hos-
pital for Tropical Diseases (HTD) in London, an enzyme-
linked immunosorbent assay (ELISA) measuring CE-specific
total IgG is the main serologic test used for diagnosis and
follow-up. However, our experience with this test is that al-
though there may be a gradual decrease in optical density
(OD) over time following treatment, the test result rarely
becomes negative even after many years, even in those whose
disease is apparently cured. Similarly, serial radiology is often
unreliable in establishing parasitologic cure; cysts killed by
chemotherapy may persist and post-operative defects cannot
always be distinguished from viable cysts.
Previous studies have reported that IgG subclasses 1–4 are
differentially expressed in patients with chronic helminthic
infections.9–11 Similarly, cross-sectional studies of patients
with CE using an ELISA incorporating partially purified hy-
datid cyst fluid antigen B have found a predominance of IgG1
and IgG4 expression in serum.12–15 Moreover, serum concen-
trations of IgG4 are greater in patients with symptomatic CE
compared with those with asymptomatic disease.15 It has
therefore been suggested that IgG subclass measurements
may provide a more sensitive index of disease activity than
CE-specific total IgG.
Patients at HTD with symptomatic CE are treated and fol-
lowed-up for many years with detailed longitudinal monitor-
ing of clinical, radiologic, and serologic parameters. In this
study, we aimed to conduct a retrospective longitudinal analy-
sis of IgG subclass expression in patients with treated CE to
determine whether serum concentrations of these subclass
antibodies provide a better correlate of CE activity compared
with CE-specific total IgG.
PATIENTS AND METHODS
Patients. A retrospective study of patients with CE was
conducted at HTD after approval from the University Col-
lege London Hospitals Committee on the Ethics for Human
Research. A clinical database cross-checked with laboratory
records was used to identify patients with diagnoses of symp-
tomatic CE between 1990 and 2000. Serial serum samples
obtained from these patients at the time of diagnosis and
during out-patient follow-up had been stored at −20°C. Sero-
logic and radiologic assessments of clinically quiescent CE
were made at least annually and often more frequently. Pa-
tients were included in this study if the case definition for CE
was fulfilled and if sera had been stored at the time of initial
diagnosis of active disease and at two or more follow-up time
points. There was no selection of cases based upon previous
serologic information. Using patient clinical records, we re-
corded the following data: demographic details, anatomic lo-
cations of cysts, clinical complications, results of radiologic
investigations, details of surgical procedures, anthelminthic
treatment, and histopathology of surgically resected speci-
mens. The clinical and radiologic follow-up records of each
patient were reviewed by two investigators (SDL and PLC).
Before the serologic results of this study were known, patients
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were categorized as having cured or inactive disease and epi-
sodes of relapse were also identified. Archived sera from pa-
tients who had been investigated for possible CE but who had
been found to have a different pathology were used as nega-
tive controls.
Treatment. The combined medical and surgical approach
to treatment of CE at this institution has been previously
reported.16 Where possible, patients receive albendazole, 400
mg twice a day for  3 months, combined with praziquantel,
40 mg/kg/day for two weeks prior to surgical intervention. A
minority of patients in this series were treated by medical
means alone, using repeated courses of albendazole in com-
bination with a single course of praziquantel. The most com-
mon surgical procedure performed was cystectomy using a
freezing cone to prevent intra-operative spillage of cyst con-
tents. Two patients were treated surgically by the puncture,
aspiration, injection, reaspiration (PAIR) procedure.17
Definitions. Cases. Cases of CE were defined as patients
with 1) histologically confirmed CE or 2) radiologic imaging
results consistent with CE and positive serology.
Cure. A patient with CE was defined as having cured dis-
ease if the following three criteria were fulfilled: 1) complete
surgical resection of all cyst material without spillage of cyst
contents; 2) treatment with albendazole, 400 mg twice a day
for  3 months plus praziquantel, 40 mg/kg/day for two
weeks; and 3) no clinical or radiologic evidence of recurrence
during  3 years of follow-up.
Inactive. A patient with CE was defined as having inactive
disease if the following three criteria were fulfilled: 1) surgical
resection was not performed, was incomplete, or was associ-
ated with intra-operative spillage; 2) anthelminthic treatment
with albendazole, 400 mg twice a day for  3 months plus
praziquantel, 40 mg/kg/day for two weeks; and 3) there was
no clinical or radiologic evidence of cyst activity or recurrence
during  3 years of follow-up.
Relapse. Relapsed CE was defined as a recurrence of active
CE following a period of quiescent disease as shown by the
radiologic enlargement of existing cysts and/or the develop-
ment of new daughter cysts.
Serology. At HTD, an ELISA incorporating crude E.
granulosus horse hydatid cyst fluid antigen is the main sero-
logic test routinely used to measure total CE-specific IgG
antibody. Using cyst material from a horse rather than from a
human overcomes the problem of reduced ELISA specificity
due to contamination with human antigens. This assay has a
sensitivity of approximately 90% and a specificity of approxi-
mately 96% in detecting hepatic CE among the selected pa-
tient population at HTD (Chiodini PL, unpublished data).
Suspected cases with borderline positivity may be further
tested with an immunoblot. Complement fixation tests were
not performed in this study because our own experience is
that this test lacks sensitivity and shows significant inter-test
variability. The ELISAs were all optimized by checkerboard
titration using defined positive and negative sera and stan-
dard laboratory methods. Samples from the same patient
were analyzed concurrently. The OD cut-off for each of the
five assays was determined as the mean + 3 SD of the negative
control sera (n  20).
In these assays, 200-L volumes were used throughout un-
less otherwise stated. Immunolon-II high-binding microtiter
plates (Dynatech, Chantilly, VA) were coated overnight at
room temperature with centrifuged crude hydatid cyst fluid (9
g/mL). Plates were washed four times with phosphate-
buffered saline, pH 7.2, 0.05% Tween (PBS-Tween) and the
wells were then blocked with 3% non-fat milk in PBS-Tween
for 60 minutes at room temperature. For the assays for total
IgG, IgG1, IgG2, IgG3, and IgG4, patient sera were diluted in
PBS-Tween 1:500, 1:200, 1:100, 1:50, and 1:50, respectively.
Diluted sera were incubated in duplicate wells of the micro-
titer plate for 90 minutes at 30°C and the plates were then
washed four times with PBS-Tween. The different assays
were then continued as follows.
Total IgG assay. Rabbit anti-human horseradish peroxi-
dase−conjugated IgG (Dako, Ely, Cambridgeshire, United
Kingdom) diluted 1:4,000 in PBS-Tween was added to each
well and the plate was incubated for 90 minutes at 30°C. The
plate was then washed four times with PBS-Tween. A sub-
strate solution of 4 mg/ml of o-phenylenediamine dihydro-
chloride (Sigma, St. Louis, MO) plus 0.005% hydrogen per-
oxide was added and incubated at room temperature for
15−20 minutes. Color development was stopped with 2.5M
sulfuric acid (30 L) and absorbance values (ODs) were mea-
sured at 490 nm with an ELISA plate reader.
IgG subclass assays. For the IgG subclass assays, monoclo-
nal mouse anti-human IgG1, IgG2, IgG3, and IgG4 (Sigma)
diluted 1:500, 1:2,500, 1:1,000 and 1:2,500, respectively, was
added to each well. The plates were then incubated for 90
minutes at 30°C and washed four times with PBS-Tween.
Peroxidase-conjugated goat anti-mouse Fc-specific IgG
(Sigma) was used as the secondary antibody and was diluted
1:24,000, 1:10,000, 1:4,000, and 1:24,000 in PBS-Tween for the
IgG1, IgG2, IgG3, and IgG4 assays, respectively. Plates were
incubated for 60 minutes at 30°C and the microtiter plate was
then washed four times with PBS-Tween. Substrate solution
was then added and the plate was developed and read as
described for the total IgG assay.
Western blots. Crude E. granulosus antigen from horse hy-
datid cyst fluid was separated alongside molecular weight
markers using polyacrylamide gel electrophoresis according
to standard procedures.18 The 12% acrylamide resolving gel
was overlaid with a 5% stacking gel. The separated antigens
were transferred onto a nitrocellulose (NC) membrane (Hy-
bond-P; Amersham Pharmacia Biotech, Little Chalfont,
Bucks, United Kingdom) using a Semi-Phor semi-dry transfer
unit (Hoefer Scientific Instruments, San Francisco, CA). Be-
fore immunodetection, the NC membrane was blocked with
3% non-fat milk in 50 mM PBS (Blotto). The NC membrane
was washed three times with 50 mM PBS, 0.05% Tween, cut
into strips approximately 4 mm wide, and placed in a multi-
channel plastic tray. One milliliter of a diluted serum (1:50 in
blotto) was applied to each NC strip and incubated for one
hour at room temperature. The blots were then washed three
times with PBS, 0.05% Tween, and goat anti-human IgG con-
jugated with horseradish peroxidase diluted 1:500 in blotto
was added to each NC strip and incubated for one hour at
room temperature. The strips were washed again. Color de-
velopment of the bands was achieved by incubating each NC
strip for 30 minutes with chloronaphthol (3% 4-chloro-1-
naphthol in absolute alcohol) diluted 1:100 in 50 mM Tris-
HCl, pH 7.6, 0.03% hydrogen peroxide. The reaction was
terminated by dilution of the substrate in a large volume of
distilled water.
Data analysis. An OD at diagnosis  0.25 was taken as the
cut-off above which an assay might potentially provide useful
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information for post-treatment follow-up. The ELISA ODs
increased in a proportion of the patients in the three months
following surgical treatment of CE cysts, presumably because
of antigen release. Depending on which was the greater, ei-
ther the OD at diagnosis or the post-operative (< 3 months)
OD was selected as the baseline value for post-treatment se-
rologic follow-up. The proportion of patients with a change in
OD (OD)  0.2 and  0.5 during follow up were deter-
mined for each assay. Among patients with cured or inactive
disease, group comparisons were made between peak ODs
and ODs of the latest follow-up serum samples. Since the
ODs were normally distributed, parametric statistical tests
were used for group comparisons. Prism version 2.0 software
(GraphPad Software Inc., San Diego, CA) was used for sta-
tistical analysis.
RESULTS
Cases of CE. Twenty eight patients (14 males and 14 fe-
males) fulfilled the inclusion criteria. Their mean ± SD age
was 37.1 ± 15.6 years and all but one were immigrants to the
United Kingdom from countries in the Mediterranean, Bal-
kans, or the Middle East. Cysts were confined to the abdomen
in 19 patients (hepatic only  14, splenic only  2, multiple
organs  3), were intrathoracic in three patients, and were
present in both the thorax and abdomen in four patients;
pelvic disease and spinal disease each occurred in one patient.
Cysts were single in 13 patients and multiple in 15 patients.
All 28 patients received anthelminthic treatment (minimum
treatment of albendazole, 400 mg twice a day for  3 months,
plus praziquantel, 40 mg/kg/day for two weeks). In addition,
25 of the patients underwent surgical procedures. The mean ±
SD duration of follow-up after diagnosis was 5.5 ± 2.6 years
(range 3−12 years). Fifteen patients fulfilled the case defi-
nition for cure’ and 11 for inactive disease. Relapse occurred
in two patients. The mean number of serial serum samples
analyzed per patient was 8.1 (range  3−34).
Serology at diagnosis. Cut-off ODs (mean + 3 SD) derived
from analysis of negative control sera were low for each of the
assays: total IgG (0.217), IgG1 (0.028), IgG2 (0.168), IgG3
(0.163), and IgG4 (0.009) (Figure 1). Among the cases of CE
studied, the number with positive serology ( cut-off level) at
diagnosis was 28 of 28 (total IgG), 28 of 28 (IgG1), 26 of 28
(IgG2), 13 of 28 (IgG3), and 23 of 28 (IgG4). Thus, the total
IgG, IgG1, and IgG2 assays had greater diagnostic sensitivity
than the IgG3 and IgG4 assays. Similarly, the mean ± SD
ODs obtained with the total IgG, IgG1, and IgG2 ELISAs
(0.956 ± 0.204, 0.805 ± 0.326, and 1.216 ± 0.539, respectively)
were significantly greater than those of the IgG3 and IgG4
assays (0.389 ± 0.608 and 0.524 ± 0.395, respectively) (Figure 1).
The proportions of patients at diagnosis with an OD  0.25
obtained with the total IgG, IgG1, and IgG2 ELISAs were 28
of 28, 25 of 28 and 26 of 28, respectively, compared with 12 of
28 and 17 of 28 with the IgG3 and IgG4 ELISAs, respectively.
These results indicated that measurement of IgG3 and IgG4
subclasses would not be useful for post-treatment follow-up
of a significant proportion of patients.
Serology in patients with cured CE. Patients with cured
disease (n  15) were followed-up for a mean ± SD of 4.9 ±
1.8 years. The mean OD obtained with each of the five ELI-
SAs decreased substantially between the peak values during
active disease and values when cured (Table 1). The greatest
mean decrease in OD (OD) was observed with the IgG2
assay and this was significantly greater than the mean OD
with the total IgG assay.
A OD  0.2 was seen in the great majority of patients
with the total IgG, IgG1, and IgG2 assays, but in compara-
tively few with the IgG3 and IgG4 assays (Table 1). When the
total IgG, IgG1, and IgG2 assays were compared, the propor-
tion of patients with a OD  0.5 was much smaller with the
total IgG assay. In view of this observation, serial longitudinal
changes in IgG1, IgG2, and total IgG were plotted for the
FIGURE 1. Total IgG, IgG1, IgG2, IgG3, and IgG4 antibody levels
measured by an enzyme-linked immunosorbent assay in serum
samples from patients with active symptomatic cystic echinococcosis
(CE) (n  28) and controls (Con) who did not have CE (n  20).
The graph shows the optical density (O.D.) values for each sample
analyzed. Mean OD values in the CE groups are indicated by the
horizontal bars.
TABLE 1
Mean ± SD ELISA OD values of total Echinococcus-specific IgG and IgG subclass antibodies in patients with cystic echinococcosis (n 15) at
diagnosis and following cure*
Peak OD Cured OD OD† No.  OD  0.2 No.  OD  0.5
Total IgG 0.974 ± 0.134 0.442 ± 0.213 0.532 ± 0.166 15 7
IgG1 0.886 ± 0.254 0.265 ± 0.213 0.638 ± 0.215 15 11
IgG2 1.123 ± 0.564 0.354 ± 0.201 0.772 ± 0.453 13 12
IgG3 0.211 ± 0.212 0.059 ± 0.067 0.148 ± 0.172 5 1
IgG4 0.449 ± 0.412 0.080 ± 0.412 0.418 ± 0.34 8 7
* The mean post-treatment decrease in OD (OD) and the number of patients with a post-treatment decrease in OD  0.2 (No.  OD  0.2) and 0.5 (No.  OD  0.5) are given. ELISA
 enzyme-linked immunosorbent assay; OD  optical density.
† By t-test. Total IgG vs IgG1 (P  0.110). Total IgG vs IgG2 (P  0.041).
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patients (n  8) in whom the convalescent total IgG OD
remained > 0.5 despite cure (Figure 2). In the majority of
these cases, the dynamic range of the IgG2 ODs was greater
than that of the total IgG and IgG1 ELISAs. Furthermore, in
some of the patients (e.g., H1, H4, and H12), ODs for the
total IgG and IgG1 ELISAs remained persistently elevated
post-treatment, whereas a much greater reduction was seen in
ODs obtained with the IgG2 assay.
Serology in patients with inactive CE. The patients with
inactive CE (n 11) were followed-up for a mean ± SD of 5.5
± 2.6 years. The mean OD obtained with each of the five
different ELISAs decreased following treatment (Table 2);
decreases from the peak value were statistically significant for
all assays except for the IgG3 ELISA. The greatest decrease
in mean OD was seen with the IgG2 ELISA and a decrease
0.2 or 0.5 occurred in a greater proportion of patients tested
with this assay compared with the others (Table 2). The mean
ODs in the inactive group were far smaller than those in the
cured group with the IgG1 (P < 0.001) and the total IgG (P <
0.001) assays. In contrast, the decrease in OD with the IgG2
assay was of similar magnitude when the cured and inactive
groups were compared (P  0.130).
Serology and relapsed CE. Relapse of CE occurred in two
patients during follow-up (Figure 3). Relapse of disease in
patient H2 was accompanied by a substantial increase in CE-
specific total IgG, IgG1, and IgG2. However, relapse of dis-
ease in patient H31 was accompanied by a marked increase in
OD only with the IgG2 ELISA; the ODs of the total IgG and
IgG1 remained < 0.4.
Western blots. Having demonstrated that the IgG2 anti-
body response appeared to correlate better with CE activity
compared with the other subclasses, we made an attempt to
determine the predominant parasite antigen recognized by
IgG2 subclass antibodies. Eight serum samples were selected
from patient H2 at time points when the patient’s disease was
diagnosed, post-treatment, during active relapse, and when
disease was again inactive (Figure 3). Western blots to detect
CE-specific total IgG in the serum at the time of diagnosis of
CE showed multiple bands of approximately 110−120, 38, 24,
16, and 8 kD. In contrast, the blots to detect IgG2 showed a
dominant 8-kD band and weak bands of 38 and 100−120 kD.
Following treatment, these bands in the IgG2 blots were
barely visible but reappeared with a dominant 8-kD band
during the patient’s disease relapse. Thus, we demonstrated
for patient H2 that CE-specific IgG2 antibodies predomi-
nantly bound to the 8-kD subunit of E. granulosus antigen B
at diagnosis and during disease relapse.
DISCUSSION
This study provides a longitudinal assessment of changes in
Echinococcus-specific total IgG and IgG subclass antibody
responses in patients with CE receiving treatment for symp-
tomatic disease. The detailed clinical, radiologic, and sero-
logic follow-up of these patients longitudinally over a 3−12-
year period provided the opportunity to correlate IgG sub-
class antibody responses with treatment outcome, whereas
previous studies have been cross-sectional in design.12–15,19
We found that at diagnosis the ELISA OD was significantly
elevated in a greater proportion of patients with the total IgG,
IgG1, and IgG2 assays compared with the IgG3 and IgG4
assays. Importantly, serum concentrations of CE-specific
IgG2 correlated most strongly with clinical outcome.
In the present study, an ELISA was used that incorporated
crude E. granulosus hydatid cyst fluid rather than purified
antigen (antigen B or antigen 5) as used in previous stud-
ies.12,13,15,19 Our rationale was that the broad diversity of an-
tigens present in crude hydatid cyst fluid might enhance de-
tection of subclass antibodies with different antigen specifici-
ties. Despite using crude hydatid cyst fluid in the ELISAs,
background OD values among the negative controls were
low. Furthermore, a wide range of ODs was observed in all
four assays used and were in general higher than those gen-
erated in assays incorporating purified antigen B. Although
some previous studies12–15 found a predominance of IgG1
and/or IgG4 antibody responses in patients with symptomatic
CE at diagnosis, our data agree with those of Ramzy and
others, who using crude hydatid cyst fluid as antigen, found
that ELISAs for total IgG, IgG1, and IgG2 antibodies were
the most sensitive.20 In the present study, low IgG3- and
IgG4-specific antibody levels in a significant proportion of
patients with CE at diagnosis effectively excluded these anti-
body subclasses as useful serologic markers for post-
treatment follow-up.
Although there is no definitive test of cure among patients
treated for symptomatic advanced CE, we believe that our
case definition provided a very high likelihood of cure. These
data confirm our previous clinical experience that detection
of CE-specific total IgG antibody levels, while providing the
basis for a sensitive diagnostic test, are unhelpful in serologic
follow-up in a significant proportion of patients with CE. In
contrast, in the present study, the broad dynamic range of
serum IgG2 antibody concentrations and the correlation with
treatment response and with relapse suggest that serum CE-
specific IgG2 antibody concentrations may provide a useful
index of post-treatment disease activity.
Eleven of the patients with CE were classified as having
inactive disease because they were treated by medical means
alone or because it was not possible to remove all cysts in
some patients with extensive disease. However, all received
chemotherapy and showed a clinical and radiologic response
to treatment without relapse over many years of follow-up. It
is likely that many of these patients were actually cured of
their disease. The presence of residual dead cyst material may
have provided an ongoing antigenic stimulus to antibody pro-
duction and, in keeping with this, the post-treatment changes
in antibody levels (ODs) for patients classified as having
inactive disease were in general smaller than those with cured
disease (Tables 1 and 2). The notable exception to this was
the IgG2 assay, which showed similar post-treatment ODs
in both cured and inactive disease groups. It is possible that
IgG2 concentrations may correlate more closely with cyst vi-
ability and may be independent of the presence of persistent
dead cyst material. More prolonged follow-up of this cohort
of patients will establish whether indeed this is the case.
In clinical practice, early detection of relapse of CE may be
difficult. In patient H2, a marked increase in concentrations
of total IgG, IgG1, and IgG2 antibodies all correlated with
disease relapse (Figure 3). In contrast, it was striking that
specific IgG2 was the only serologic correlate of disease re-
lapse in patient H31 (Figure 3). Had IgG subclass measure-
ments been made in this patient during follow-up, the increas-
ing concentration of IgG2 over several years might have
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FIGURE 2. Changes in serum concentrations of total IgG (), IgG1 (), and IgG2 () antibodies among patients (n  8) in whom cystic
echinococcosis (CE) was cured by surgery and anthelminthic chemotherapy but in whom the CE-specific total IgG enzyme-linked immunosorbent
assay (ELISA) optical density (OD) values remained 0.5 during follow-up. The ELISA ODs are plotted against duration of follow-up with time
0 representing the time of diagnosis and initiation of treatment.
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alerted the clinician to the disease activity before it became
clinically and radiologically apparent. This information may
have led to earlier treatment and thereby limited the morbid-
ity associated with this relapse.
In contrast to our results, previous studies of the correla-
tion of serum concentrations of IgG subclass antibody re-
sponses in patients with symptomatic CE have indicated that
IgG4 antibodies might correlate well with the activity of
CE.15,19 However, in light of the present findings, it is inter-
esting to note that the IgG2 antibody response has previously
been observed in patients with cysts undergoing natural in-
volution, appearing on ultrasound as a solid mass with or
without calcification12 (classified as type IV or V cysts, re-
spectively).4 Several factors may underlie the differences be-
tween our data and those of previous studies. First, previous
studies have been limited by a cross-sectional design, whereas
in the present study the detailed clinical and radiologic fol-
low-up of our cohort of patients with CE over many years
permitted longitudinal analysis of changes in IgG subclass
antibody responses over time. Second, we used crude horse
hydatid cyst antigen, whereas recent studies have most com-
monly used partially purified hydatid cyst fluid antigen
B,14,15,19 which appears to preferentially bind IgG4 antibod-
ies.14,21 Indeed, the lack of standardized assays in serologic
studies of CE make it difficult to make comparisons between
different laboratories. Standardization would greatly facili-
tate progress of research in this field. Furthermore, the de-
velopment of the World Health Organization standardized
radiologic classification of cysts4 will further help compara-
bility of studies.
Since our assays used crude hydatid cyst fluid as antigen, we
proceeded to determine which was the immunodominant an-
tigen recognized by the IgG2 subclass. The lipoprotein anti-
gen B and antigen 5 are the two major immunodominant
antigens that have been identified in E. granulosus cysts and
are the most widely used antigens in current assays for im-
munodiagnosis of CE.22 Antigen B is a polymeric lipoprotein
with a molecular mass of 120 kD that dissociates into 8-, 16-,
and 24-kD subunits under reducing conditions on immuno-
blots, whereas antigen 5 is a very high molecular mass lipo-
protein complex that dissociates into 38 and 22−24-kD sub-
units. We found that IgG2 predominantly bound to the 8-kD
subunit of antigen B. Thus, the difference between our results
and previous data is not simply explained by use of crude cyst
fluid as antigen instead of partially purified antigen B.
In conclusion, using ELISAs that incorporated crude E.
granulosus horse hydatid cyst fluid antigen and CE-specific
total IgG, IgG1, and IgG2 were found to be sensitive corre-
lates of disease at the time of clinical presentation. However,
the IgG2 antibody response was the best correlate of disease
activity during post-treatment follow-up. Further prospective
evaluation of the IgG2 antibody response in patients during
treatment is warranted using standardized serologic and ra-
diologic reporting methods.
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FIGURE 3. Changes in total IgG (), IgG1 (), and IgG2 ()
enzyme-linked immunosorbent assay optical density (OD) values in
two patients in whom relapse of cystic echinococcosis (CE) was de-
tected during follow-up. The times at which treatment was given (T)
and the time at which a disease relapse occurred (R) are indicated.
TABLE 2
Mean ± SD ELISA OD values of Echinococcus-specific total IgG and IgG subclasses in patients (n  11) at diagnosis of active cystic
echinococcosis and during inactive disease*
Peak OD Inactive OD  OD† No.  OD  0.2 No.  OD  0.5
Total IgG 0.925 ± 0.284 0.658 ± 0.318 0.267 ± 0.191 7 1
IgG1 0.703 ± 0.403 0.406 ± 0.390 0.298 ± 0.214 7 3
IgG2 1.318 ± 0.482 0.799 ± 0.466 0.520 ± 0.327 9 5
IgG3 0.494 ± 0.707 0.370 ± 0.495 0.195 ± 0.364 3 2
IgG4 0.616 ± 0.332 0.290 ± 0.330 0.297 ± 0.272 6 2
* The mean post-treatment decrease in OD (OD) and the number of patients with a post-treatment decrease in OD  0.2 (No.  OD  0.2) and 0.5 (No.  OD  0.5) are given. ELISA
 enzyme-linked immunosorbent assay. OD  optical density.
† By t-test. Total IgG vs IgG1 (P  0.729). Total IgG vs IgG2 (P  0.039).
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